Related Experiment Video
Updated: Jun 22, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Long-term survival after cardiac arrest in hypertrophic cardiomyopathy
Barry J Maron1, Tammy S Haas, Kevin M Shannon
1Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota 55407, USA. hcm.maron@mhif.org
Insights
Patients with hypertrophic cardiomyopathy (HCM) experiencing cardiac arrest can achieve long-term survival, even up to 30 years. Many survivors experience few heart failure symptoms, highlighting the unpredictable nature of HCM arrhythmias.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Disease Research
Background:
- Hypertrophic cardiomyopathy (HCM) patients with aborted cardiac arrest represent a high-risk group with uncertain long-term outcomes.
- Previous studies have not fully defined the prognosis for HCM patients after major arrhythmic events.
Purpose of the Study:
- To elucidate the long-term natural history of hypertrophic cardiomyopathy (HCM).
- To assess the outcomes of HCM patients following cardiac arrest or appropriate implantable cardioverter-defibrillator (ICD) shocks.
Main Methods:
- Prospective assessment of 39 hypertrophic cardiomyopathy (HCM) patients from the Minneapolis Heart Institute registry.
- Patients included those who experienced cardiac arrest (n=21) or received an appropriate ICD shock (n=18).
Main Results:
- 82% of patients (32/39) survived their initial arrhythmic event, with follow-up extending up to 30 years.
- Of survivors, 47% experienced no further events, while 53% had additional cardiac arrests or ICD interventions.
- Annual HCM-related mortality was 1.4%, and 91% of survivors had no or mild heart failure symptoms.
Conclusions:
- Long-term survival (up to 30 years) is possible for hypertrophic cardiomyopathy (HCM) patients after cardiac arrest, with or without ICDs.
- Disabling heart failure symptoms are uncommon in the long term following these arrhythmic events.
- The arrhythmogenic substrate in HCM can be unpredictable, remaining dormant for extended periods.
Background:
Patients with hypertrophic cardiomyopathy (HCM) and aborted cardiac arrest are generally regarded as a high-risk subgroup susceptible to future major cardiac events and an unfavorable prognosis. However, outcome over extended time periods after major arrhythmic events is unresolved in such HCM patients.
Objective:
This study sought to more completely define the natural history of HCM.
Methods:
Of 916 HCM patients in the Minneapolis Heart Institute registry, 39 experienced either cardiac arrest (n = 21) or an appropriate shock from a prophylactically implanted cardioverter-defibrillator (ICD) (n = 18), and were assessed prospectively.
Results:
Age at initial arrhythmic event was 34 +/- 17 years (range 8 to 68; 67% <40 years). Of the 39 study patients, 32 (82%) survived after their initial cardiac event (for 9.4 +/- 7.6 years; up to 30 years), including 14 patients for >or=10 years (36%) and 4 patients >or=20 years (10%). Of the 32 survivors, 15 (47%) have not experienced subsequent events, and 17 (53%) had >or=1 additional cardiac arrest or appropriate ICD intervention. Annual HCM-related mortality was 1.4%, similar to general HCM populations, and 88% of patients were free of HCM-related death over the follow-up period. Survival from potentially lethal arrhythmias was associated with no or only mild heart failure symptoms in 29 of 32 patients (91%) at most recent evaluation.
Conclusion:
In HCM, long-term survival up to 30 years may follow cardiac arrest with or without ICD intervention. Disabling heart failure symptoms were uncommon after these arrhythmic events, at last follow-up. These novel observations regarding the natural history of HCM underscore the unpredictability of the arrhythmogenic substrate, which may remain dormant over extended periods of time.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Pathophysiology of Heart Failure
Cardiomyopathy VI: Nursing Management

